Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

MorphoSys AG: MorphoSys Strengthens Patent Position on anti-CD19 Cancer Program MOR208



   MorphoSys AG: MorphoSys Strengthens Patent Position on anti-CD19 Cancer
                                Program MOR208

MorphoSys AG / MorphoSys Strengthens Patent Position on anti-CD19 Cancer
Program MOR208 . Ad hoc announcement according to § 15 WpHG. Processed and
transmitted by Thomson Reuters ONE. The issuer is solely responsible for the
content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY)  announced 
today that the  US Patent and  Trademark Office (USPTO)  has granted a  patent 
covering the Company's cancer compound  MOR208. The new patent (US  8,524,867) 
covers the antibody's protein sequence as well as pharmaceutical  compositions 
comprising the same. The new patent has  a scheduled expiry date in 2029,  not 
including any  potential  patent  office  or  regulatory  extensions,  and  is 
licensed to MorphoSys AG from Xencor, Inc.

Dr. Marlies Sproll, Chief Scientific  Officer of MorphoSys AG, commented:  "We 
are very optimistic  about the  prospects of MOR208  and are  building a  rich 
scientific, medical and commercial  package around this  program, in order  to 
lay the groundwork for future commercialization."

MOR208 is a humanized  monoclonal antibody that targets  the antigen CD19  for 
treatment of B  cell malignancies  and autoimmune diseases.  The antibody  has 
been  engineered   to   possess  significantly   enhanced   antibody-dependent 
cell-mediated cytotoxicity (ADCC),  thus improving a  key mechanism for  tumor 
cell  killing  and  offering  potential  for  enhanced  efficacy  compared  to 
traditional antibodies for the treatment of cancer.

MOR208 has  shown in  a  Phase 1/2a  trial  encouraging signs  of  preliminary 
anti-tumor activity  and  an acceptable  safety  and tolerability  profile  in 
patients with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL)
or small  lymphocytic lymphoma  (SLL).  The study  results showed  an  overall 
response rate of 29.6% (according to IWCLL 2008 criteria) based on the  safety 
population of  the trial  (n=27).  MorphoSys is  conducting Phase  2  clinical 
trials of  MOR208 in  patients with  non-Hodgkin's lymphoma  (NHL) and  B-cell 
acute lymphoblastic leukemia (B-ALL).

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners,  MorphoSys has built a  therapeutic 
pipeline of more than 80 human  antibody drug candidates for the treatment  of 
cancer, rheumatoid arthritis,  and Alzheimer's  disease, to name  just a  few. 
With its ongoing commitment to  new antibody technology and drug  development, 
MorphoSys is focused on making the healthcare products of tomorrow.  MorphoSys 
is listed on the  Frankfurt Stock Exchange under  the symbol MOR. For  regular 
updates about MorphoSys, visit http://www.morphosys.com

HuCAL^®, HuCAL GOLD^®, HuCAL  PLATINUM^®, CysDisplay^®, RapMAT^®, arYla^®  and 
Ylanthia^® and  100 billion  high potentials^®  are registered  trademarks  of 
MorphoSys AG.

Slonomics^® is  a  registered  trademark  of  Sloning  BioTechnology  GmbH,  a 
subsidiary of MorphoSys AG.

 

This communication contains certain forward-looking statements concerning  the 
MorphoSys group of companies. The forward-looking statements contained  herein 
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties.  Should actual conditions  differ from the  Company's 
assumptions, actual results  and actions  may differ  from those  anticipated. 
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.

 

 

 

For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com

Media Release (PDF)

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE
HUG#1737008

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / Munich Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All
Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement